- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01004211
Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging
January 13, 2018 updated by: Paolo Puppo
A Phase III Prospective Multicenter Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging.
To date, fluorescence and narrow band imaging cystoscopy have been tested in many prospective within patient trials but only as an "add on" procedure.
This results in a bias that does not allow to determine the real impact of such innovative technologies on bladder cancer management.
Hereby we propose the first prospective randomized trial which compares narrow band imaging trans urethral resection as a stand alone procedure versus white light transurethral resection.
The primary end point is to assess the recurrence rate of bladder cancer lesions with each treatment modality.
The study is designed to disclose an inferior recurrence rate (estimated 10%) in the group treated by narrow band imaging transurethral resection respect to the control group, treated by standard transurethral resection.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
188
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Genoa, Italy, 16132
- National Institute for Cancer Research (IST)
-
Imperia, Italy
- Centro Urologico di Eccellenza ASL 1
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- All patients must be older than 18 years of age and female patients who are pregnant, breast feeding or not on adequate contraceptive measures will be excluded.
- All patients will provide a written informed consent prior to the study.
- Consecutive patients from 2 centers in Liguria (National Institute for Cancer Research - Genova and Centro Urologico di Eccellenza ASL 1 - Imperia) with overt or suspected non muscle invasive bladder cancer, including Cis detected by mean of random biopsies or a positive urinary cytology, will be included in the study and randomized to 2 treatments A, B arms.
Exclusion Criteria:
- Patients with muscle invasive bladder cancer will be excluded.
- Patients submitted to immediate radical cystectomy after transurethral resection, irrespective of the clinical stage, will be excluded.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Standard transurethral resection
Patients will be submitted to standard white light transurethral resection and/or cold cup biopsies of all visible lesions known or suspected to be bladder cancer; 6 random cold cup biopsies from healthy mucosa of bladder trigone, anterior, posterior and lateral walls will be taken in case of a second transurethral resection of newly diagnosed high grade non muscle invasive bladder cancer or of recurrent high grade non muscle invasive bladder cancer
|
Transurethral resection of bladder lesion by mean of standard white light
|
|
Experimental: Narrow band imaging transurethral resection
The system will be switched to narrow band imaging by simply pushing a button.
Transurethral resection and/or cold cup biopsies of all visible lesions known or suspected to be bladder cancer will be performed; 6 random cold cup biopsies from healthy mucosa of bladder trigone, anterior, posterior and lateral walls will be taken in case of a second transurethral resection of newly diagnosed high grade non muscle invasive bladder cancer or of recurrent high grade non muscle invasive bladder cancer.
|
Transurethral resection of bladder lesion by mean of narrow band imaging
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Recurrence free survival rate
Time Frame: One year
|
One year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Detection rate
Time Frame: At the end of enrollment
|
At the end of enrollment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Paolo Puppo, MD, National Institute for Cancer Research, Genoa, Italy
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Naselli A, Introini C, Timossi L, Spina B, Fontana V, Pezzi R, Germinale F, Bertolotto F, Puppo P. A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. Eur Urol. 2012 May;61(5):908-13. doi: 10.1016/j.eururo.2012.01.018. Epub 2012 Jan 20.
- Naselli A, Introini C, Bertolotto F, Spina B, Puppo P. Narrow band imaging for detecting residual/recurrent cancerous tissue during second transurethral resection of newly diagnosed non-muscle-invasive high-grade bladder cancer. BJU Int. 2010 Jan;105(2):208-11. doi: 10.1111/j.1464-410X.2009.08701.x. Epub 2009 Jun 22.
- Naselli A, Introini C, Bertolotto F, Spina B, Puppo P. Feasibility of transurethral resection of bladder lesion performed entirely by means of narrow-band imaging. J Endourol. 2010 Jul;24(7):1131-4. doi: 10.1089/end.2010.0042.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2009
Primary Completion (Actual)
October 1, 2011
Study Completion (Actual)
October 1, 2011
Study Registration Dates
First Submitted
October 28, 2009
First Submitted That Met QC Criteria
October 28, 2009
First Posted (Estimate)
October 29, 2009
Study Record Updates
Last Update Posted (Actual)
January 17, 2018
Last Update Submitted That Met QC Criteria
January 13, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IST-NBI-2009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Muscle Invasive Bladder Cancer
-
Jecho Biopharmaceuticals Co., Ltd.Not yet recruitingHigh Risk Non-muscle Invasive Bladder Cancer
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Not yet recruitingHigh-risk Non-muscle-invasive Bladder CancerChina
-
Aura BiosciencesRecruitingUrothelial Carcinoma Bladder | NMIBC | Non-muscle-invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial Carcinoma | Non-Muscle Invasive Bladder Neoplasms | Non-Muscle Invasive Bladder CarcinomaUnited States, Australia
-
University of Roma La SapienzaRecruitingNon-muscle-invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial Carcinoma | High Risk Non-Muscle Invasive Bladder Urothelial CarcinomaItaly
-
University of VirginiaAmerican Cancer Society, Inc.; Integrated Translational Health Research Institute...RecruitingBladder Cancer | Muscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder CancerUnited States
-
AstraZenecaHospital Israelita Albert EinsteinCompletedUrothelial Carcinoma | Muscle-invasive Bladder Cancer | Non Muscle Invasive Bladder CancerBrazil
-
Nucleix Ltd.CompletedNon Muscle Invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial CarcinomaUnited States
-
Yunnan Cancer HospitalRecruitingNon-Muscle-Invasive Bladder CancerChina
-
Memorial Sloan Kettering Cancer CenterRecruitingNon-Muscle Invasive Bladder CancerUnited States
-
Shaogang WangRecruitingNon-Muscle-Invasive Bladder Cancer (NMIBC)China
Clinical Trials on Standard transurethral resection
-
Chinese University of Hong KongThe University of Hong Kong; Queen Elizabeth Hospital, Hong Kong; North District... and other collaboratorsCompleted
-
Sohag UniversityCompletedBPH | Ejaculatory DysfunctionEgypt
-
Allama Iqbal Medical CollegeActive, not recruitingBladder Cancer | BPH (Benign Prostatic Hyperplasia) | Bladder Cancer RecurrencePakistan
-
Samsung Medical CenterCompletedBladder Pain SyndromeKorea, Republic of
-
Lahore General HospitalCompletedUrinary Bladder Neoplasms | Non-muscle Invasive Bladder CancerPakistan
-
Ain Shams UniversityCompletedBenign Prostatic HyperplasiaEgypt
-
Tongji HospitalUnknownNon-muscle Invasive Bladder Cancer
-
Lawson Health Research InstituteGyrus ACMI, Inc.CompletedBenign Prostatic Hyperplasia | BPHCanada
-
Assiut UniversityNot yet recruiting
-
Zhujiang HospitalThe First Affiliated Hospital of Anhui Medical University; The First Affiliated... and other collaboratorsUnknownTransurethral Plasmakinetic Enucleation of Prostate Versus Transurethral Resection of Prostate (ERP)Benign Prostatic HyperplasiaChina